The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure

David Wolinsky, Robert Hendel, Manuel Cerqueira, Michael Gold, Jagat Narula, Jagmeet Singh, Leslee Shaw, Gregory Thomas, Oussama Wazni, Carolyn Farnum

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.

Original languageEnglish (US)
Pages (from-to)S1-S9
JournalAmerican Journal of Cardiology
Volume116
DOIs
StatePublished - Oct 15 2015

Fingerprint

Implantable Defibrillators
Heart Failure
Heart-Assist Devices
Sudden Cardiac Death
Left Ventricular Dysfunction
Heart Transplantation
Primary Prevention
Therapeutics
Hospitalization
Morbidity
Delivery of Health Care
Costs and Cost Analysis
Equipment and Supplies
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wolinsky, D., Hendel, R., Cerqueira, M., Gold, M., Narula, J., Singh, J., ... Farnum, C. (2015). The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure. American Journal of Cardiology, 116, S1-S9. https://doi.org/10.1016/j.amjcard.2015.09.014

The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure. / Wolinsky, David; Hendel, Robert; Cerqueira, Manuel; Gold, Michael; Narula, Jagat; Singh, Jagmeet; Shaw, Leslee; Thomas, Gregory; Wazni, Oussama; Farnum, Carolyn.

In: American Journal of Cardiology, Vol. 116, 15.10.2015, p. S1-S9.

Research output: Contribution to journalArticle

Wolinsky, D, Hendel, R, Cerqueira, M, Gold, M, Narula, J, Singh, J, Shaw, L, Thomas, G, Wazni, O & Farnum, C 2015, 'The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure', American Journal of Cardiology, vol. 116, pp. S1-S9. https://doi.org/10.1016/j.amjcard.2015.09.014
Wolinsky, David ; Hendel, Robert ; Cerqueira, Manuel ; Gold, Michael ; Narula, Jagat ; Singh, Jagmeet ; Shaw, Leslee ; Thomas, Gregory ; Wazni, Oussama ; Farnum, Carolyn. / The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure. In: American Journal of Cardiology. 2015 ; Vol. 116. pp. S1-S9.
@article{c1f84561ee0d44e4b612c75568f472f2,
title = "The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure",
abstract = "Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.",
author = "David Wolinsky and Robert Hendel and Manuel Cerqueira and Michael Gold and Jagat Narula and Jagmeet Singh and Leslee Shaw and Gregory Thomas and Oussama Wazni and Carolyn Farnum",
year = "2015",
month = "10",
day = "15",
doi = "10.1016/j.amjcard.2015.09.014",
language = "English (US)",
volume = "116",
pages = "S1--S9",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure

AU - Wolinsky, David

AU - Hendel, Robert

AU - Cerqueira, Manuel

AU - Gold, Michael

AU - Narula, Jagat

AU - Singh, Jagmeet

AU - Shaw, Leslee

AU - Thomas, Gregory

AU - Wazni, Oussama

AU - Farnum, Carolyn

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.

AB - Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.

UR - http://www.scopus.com/inward/record.url?scp=84944743128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944743128&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.09.014

DO - 10.1016/j.amjcard.2015.09.014

M3 - Article

VL - 116

SP - S1-S9

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

ER -